Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
Laura C. Coates, Iain B. McInnes, Joseph F. Merola, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 12, pp. 1959-1970
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Joseph F. Merola, Robert Landewé, Iain B. McInnes, et al.
The Lancet (2022) Vol. 401, Iss. 10370, pp. 38-48
Open Access | Times Cited: 107
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
Iain B. McInnes, Akihiko Asahina, Laura C. Coates, et al.
The Lancet (2022) Vol. 401, Iss. 10370, pp. 25-37
Open Access | Times Cited: 101
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C. Coates, Robert Landewé, Iain B. McInnes, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003855-e003855
Open Access | Times Cited: 18
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Christopher T. Ritchlin, Laura C. Coates, Iain B. McInnes, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 11, pp. 1404-1414
Open Access | Times Cited: 28
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
Guillermo Sánchez-Rodríguez, L. Puig
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10305-10305
Open Access | Times Cited: 26
Biomarkers and biologics related with psoriasis and psoriatic arthritis
Weize Gao, Zhan Wang, Wenshuai Li, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110646-110646
Closed Access | Times Cited: 13
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
S. Wu, Yuanyuan Xu, Lihua Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus
Tiago Torres, Nicolò Costantino Brembilla, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
Hong Ki Min, Se Hee Kim, Hae‐Rim Kim, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13913-13913
Open Access | Times Cited: 19
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
Philip J. Mease, Lianne S. Gensler, Ana‐Maria Orbai, et al.
RMD Open (2025) Vol. 11, Iss. 2, pp. e005026-e005026
Open Access
Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis
Marta Krzysztofik, Paweł Brzewski, Przemysław J. Cuber, et al.
Pharmaceuticals (2023) Vol. 17, Iss. 1, pp. 14-14
Open Access | Times Cited: 7
Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta‐Analysis
Katie Bechman, Zijing Yang, Maryam Adas, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 5, pp. 704-714
Open Access | Times Cited: 7
Bimekizumab: A Review in Psoriatic Arthritis
Tina Nie, Matt Shirley
Drugs (2024) Vol. 84, Iss. 5, pp. 587-598
Closed Access | Times Cited: 2
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, et al.
ACR Open Rheumatology (2024) Vol. 6, Iss. 11, pp. 720-731
Open Access | Times Cited: 2
Psoriasis management tree based on comorbidity
S. Abu Amara, Anusha Pasumarthi, Neil Parikh, et al.
International Journal of Dermatology (2024)
Closed Access | Times Cited: 2
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE
Philip J. Mease, Akihiko Asahina, Dafna D. Gladman, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 2, pp. 617-628
Open Access | Times Cited: 11
Bimekizumab for the treatment of psoriatic arthritis
Yoshiya Tanaka, Stevan Shaw
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 2, pp. 155-168
Open Access | Times Cited: 6
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
Valgerður Sigurðardóttir, Anna K. Engstrom, Patric Berling, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 1190-1200
Open Access | Times Cited: 1
Bimekizumab for The Treatment of Psoriasis
Molly Thapar, Milan Patel, Kenneth B. Gordon
Immunotherapy (2024) Vol. 16, Iss. 7, pp. 431-446
Closed Access
State of the Art Review on the Treatment of Psoriatic Disease
Eleftherios Pelechas, Evripidis Kaltsonoudis, Michalis P. Migkos, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. 1, pp. 66-66
Open Access
Treatment-emergent candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with Ixekizumab: an integrated safety analysis of 25 clinical studies
Sergio Schwartzman, L. Puig, Arnon D. Cohen, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Open Access
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
M. Elaine Husni, Philip J. Mease, Joseph F. Merola, et al.
RMD Open (2024) Vol. 10, Iss. 3, pp. e004464-e004464
Open Access
Infections in psoriatic arthritis: association with treatment
Athanasios Vassilopoulos, Κonstantinos Thomas, Dimitrios Vassilopoulos
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access
Comment on: Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials
Barbara Ink, Rajan Bajracharya, Vishvesh Shende
Therapeutic Advances in Chronic Disease (2024) Vol. 15
Open Access
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies
Lars Erik Kristensen, William Tillett, Peter Nash, et al.
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top